Welcome to our dedicated page for Advanced Human Imaging Limited. news (Ticker: AHI), a resource for investors and traders seeking the latest updates and insights on Advanced Human Imaging Limited. stock.
Advanced Health Intelligence Ltd develops digital health technology centered on smartphone-based biometric screening and health risk assessment. Its updates commonly cover the AHI Biometric Health Assessment, the Health Risk Assessment report, algorithmic assets that use smartphone sensor data to estimate biometric and chronic-disease risk indicators, and the company's use of artificial intelligence in non-invasive scans.
Recurring AHI news also includes academic and regulatory validation work, commercialization updates, and partner integrations in digital health records, insurance underwriting, rewards-based health applications, and regional healthcare programs. Corporate communications may also address capital-market presentations and updates on the company's digital health solutions.
Advanced Human Imaging Limited (ASX: AHI), on February 15, 2022, appointed Nick Prosser as interim Non-executive Chairman and Dr. Katherine Iscoe as Director and CEO. This follows Vlado Bosanac's transition to Head of Strategy and Revenue Growth. Prosser brings experience from his prior role at Canberra Data Centres, valued at $1.16 billion. Dr. Iscoe, a co-founder, emphasizes opportunities in remote patient monitoring and digital health solutions. An executive services agreement for Dr. Iscoe is in progress, with terms to be announced shortly.
Advanced Human Imaging Limited (ASX: AHI, NASDAQ: AHI) has signed a binding term sheet with Vertica Health PTY Ltd, a remote monitoring provider based in South Africa. This partnership will integrate AHI's MultiScan Software Development Kit into Vertica's health risk management application, enhancing user capabilities in monitoring health risks such as metabolic syndrome and cardiovascular disease. CEO Vlado Bosanac highlighted the potential positive impact on patient outcomes and preventive healthcare delivery in South Africa and beyond.
Advanced Human Imaging Limited (ASX: AHI) announced a binding term sheet with Activate Health OÜ, a digital health provider from Estonia, on January 26, 2022. This partnership will enhance Activate's digital therapeutic platform for metabolic syndrome, affecting nearly one-third of adults globally. AHI's MultiScan Software Development Kit will integrate with Activate's platform, enabling users to assess chronic disease risk and improve health outcomes. The collaboration aims to promote prevention-focused healthcare solutions and improve the efficiency of health audits.
Advanced Human Imaging Limited (ASX:AHI, NASDAQ:AHI) has signed a binding term sheet with Peruvian telemedicine company Nextmedicall. This partnership aims to integrate AHI's MultiScan Software Development Kit into Nextmedicall's platform, enabling remote health assessments via BodyScan and FaceScan technologies. Nextmedicall plans to use this integration for early detection of chronic diseases across Latin America. The implementation is set to begin within 120 days and follows a successful pilot program with Entel Chile.
Advanced Human Imaging Limited (ASX:AHI, NASDAQ:AHI) has successfully closed its U.S. initial public offering, raising US$10.5 million by issuing 1,000,000 units priced at US$10.50 each. Each unit includes two ADSs and one warrant, with an exercise price of US$5.52 per ADS. The ADSs began trading on Nasdaq on November 19, 2021.
The funds will primarily support research, product development, and marketing, with additional investments in synergistic companies.
Advanced Human Imaging Limited (ASX:AHI) (NASDAQ:AHI) announced the pricing of its U.S. initial public offering, offering 1,000,000 units at US$10.50 each. Each unit includes two American Depositary Shares (ADSs) and a warrant for one ADS, with gross proceeds expected to reach US$10.5 million. The ADSs will begin trading on Nasdaq under the symbol "AHI" from November 19, 2021. Proceeds will fund research, product development, and general corporate purposes. The company has also granted underwriters a 45-day option for an additional 300,000 ADSs.